Nifty
:
24177.65
Sensex
:
77496.36
181.95 (0.76%)
609.45 (0.79%)
Nifty
Sensex
:
:
24177.65
77496.36
181.95 (0.76%)
609.45 (0.79%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
70/99

BSE: 539523 | NSE: ALKEM

NSE BSE
5344.00
29-Apr-2026
  • Open
  • High
  • Low
  • Previous Close
  •  5420
  •  5453.5
  •  5305.5
  •  5418.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  96480
  •  516768815.5
  •  5933.5
  •  4716.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 63,882.98
  • 27.29
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 64,297.41
  • 0.84%
  • 4.62

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.20%
  • 0.08%
  • 17.06%
  • FII
  • DII
  • Others
  • 10.15%
  • 19.75%
  • 1.76%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.16
  • 7.90
  • 3.78

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.40
  • 5.28
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.31
  • 6.45
  • 30.08

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.74
  • 29.07
  • 32.97

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.87
  • 5.07
  • 5.33

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.22
  • 20.92
  • 21.94

Earnings Forecasts:

(Updated: 18-04-2026)
Description
2024
2025
2026
2027
Adj EPS
181.11
208.63
189.69
218.51
P/E Ratio
29.92
25.97
28.57
24.80
Revenue
12804.6
14587.8
16280
17975.1
EBITDA
2512.15
3010.49
3398.5
3861.19
Net Income
2165.48
2517.06
2304.95
2656.94
ROA
13.02
13.72
12.25
13.22
P/B Ratio
5.41
4.68
4.20
3.73
ROE
19.42
19.17
15.48
15.71
FCFF
1504.49
1544.75
1261.04
1863.07
FCFF Yield
2.42
2.49
2.03
3
Net Debt
-1084.44
-2442.37
-3457.37
-4856.15
BVPS
1002.37
1157.98
1291.64
1453.21

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
3,736.82
3,374.28
10.74%
4,000.99
3,414.67
17.17%
3,371.14
3,031.82
11.19%
3,143.75
2,935.82
7.08%
Expenses
2,908.82
2,614.89
11.24%
3,080.22
2,661.84
15.72%
2,632.09
2,423.18
8.62%
2,752.46
2,533.84
8.63%
EBITDA
828.00
759.39
9.03%
920.77
752.83
22.31%
739.05
608.64
21.43%
391.29
401.98
-2.66%
EBIDTM
22.16%
22.51%
23.01%
22.05%
21.92%
20.08%
12.45%
13.69%
Other Income
143.10
92.99
53.89%
103.69
134.48
-22.90%
136.49
120.31
13.45%
145.96
88.17
65.54%
Interest
42.10
36.03
16.85%
35.02
28.14
24.45%
29.78
29.11
2.30%
28.42
26.86
5.81%
Depreciation
95.01
85.28
11.41%
93.61
78.91
18.63%
87.68
80.48
8.95%
112.49
83.43
34.83%
PBT
781.20
731.07
6.86%
895.83
780.26
14.81%
771.01
619.36
24.48%
396.34
367.34
7.89%
Tax
127.67
90.28
41.42%
116.23
78.30
48.44%
102.69
69.12
48.57%
73.33
62.86
16.66%
PAT
653.53
640.79
1.99%
779.60
701.96
11.06%
668.32
550.24
21.46%
323.01
304.48
6.09%
PATM
17.49%
18.99%
19.49%
20.56%
19.82%
18.15%
10.27%
10.37%
EPS
53.20
52.35
1.62%
63.99
57.60
11.09%
55.56
45.60
21.84%
25.58
24.56
4.15%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
14,252.70
12,964.52
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
Net Sales Growth
11.73%
2.34%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
 
Cost Of Goods Sold
5,124.18
4,121.25
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
Gross Profit
9,128.52
8,843.27
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
GP Margin
64.05%
68.21%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
Total Expenditure
11,373.59
10,452.37
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
Power & Fuel Cost
-
168.99
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
% Of Sales
-
1.30%
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
Employee Cost
-
2,453.92
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
% Of Sales
-
18.93%
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
Manufacturing Exp.
-
1,282.95
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
% Of Sales
-
9.90%
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
General & Admin Exp.
-
850.62
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
% Of Sales
-
6.56%
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
Selling & Distn. Exp.
-
1,319.76
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
% Of Sales
-
10.18%
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
Miscellaneous Exp.
-
254.88
406.87
181.00
85.84
91.05
130.67
127.28
107.99
122.20
503.69
% Of Sales
-
1.97%
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
EBITDA
2,879.11
2,512.15
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
EBITDA Margin
20.20%
19.38%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
Other Income
529.24
493.74
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
Interest
135.32
121.70
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
Depreciation
388.79
357.16
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
PBT
2,844.38
2,527.03
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Tax
419.92
311.03
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
Tax Rate
14.76%
12.31%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
PAT
2,424.46
2,166.10
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
PAT before Minority Interest
2,373.22
2,216.00
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
Minority Interest
-51.24
-49.90
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
PAT Margin
17.01%
16.71%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
PAT Growth
10.33%
20.62%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
 
EPS
202.71
181.11
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
11,984.87
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
11,924.81
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
Non-Current Liabilities
-445.76
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
Secured Loans
62.42
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
Unsecured Loans
248.49
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
Long Term Provisions
338.22
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
Current Liabilities
3,958.69
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
Trade Payables
1,839.35
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
Other Current Liabilities
1,164.24
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
366.01
Short Term Borrowings
734.89
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
Short Term Provisions
220.21
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
Total Liabilities
15,946.56
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
Net Block
2,852.31
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
Gross Block
4,719.78
4,543.69
4,050.24
4,185.64
3,723.05
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
Accumulated Depreciation
1,867.47
1,670.91
1,367.39
1,283.91
930.07
698.94
495.64
320.19
180.16
89.10
Non Current Assets
5,007.03
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
Capital Work in Progress
548.07
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
Non Current Investment
943.24
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
Long Term Loans & Adv.
508.16
203.74
139.07
154.44
93.77
90.65
111.47
133.68
185.16
142.35
Other Non Current Assets
155.25
78.60
274.70
697.18
48.55
54.19
53.82
100.11
413.74
251.03
Current Assets
10,811.19
10,411.58
8,606.42
8,433.70
6,923.27
5,487.57
4,204.40
4,013.22
2,915.32
2,768.70
Current Investments
902.26
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
Inventories
2,922.41
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
Sundry Debtors
2,466.25
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
Cash & Bank
1,563.08
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
Other Current Assets
2,957.19
237.13
244.68
239.80
834.34
757.29
566.64
567.93
302.86
236.74
Short Term Loans & Adv.
2,800.91
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
Net Current Assets
6,852.50
6,417.03
4,899.27
3,628.36
3,319.22
2,242.99
1,986.87
1,629.91
1,225.63
1,231.10
Total Assets
15,818.22
14,060.07
12,330.89
12,758.20
10,405.80
8,994.89
7,488.83
7,010.02
5,869.96
5,018.43

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
1,912.84
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
PBT
2,527.03
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Adjustment
103.80
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
Changes in Working Capital
-213.97
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
Cash after chg. in Working capital
2,416.86
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-504.02
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,298.76
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
Net Fixed Assets
75.19
-74.10
-101.58
-278.91
-115.11
-310.63
-342.15
-531.27
-390.07
160.79
Net Investments
-1,577.80
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
Others
203.85
-1,110.97
691.36
-779.99
-687.09
-170.28
176.86
200.90
464.11
128.59
Cash from Financing Activity
-810.99
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
Net Cash Inflow / Outflow
-196.91
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
Opening Cash & Equivalents
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
Closing Cash & Equivalent
-120.09
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
999.47
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
ROA
14.77%
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
ROE
19.93%
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
ROCE
21.56%
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
Fixed Asset Turnover
4.17
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
Receivable days
44.62
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
Inventory Days
52.79
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
Payable days
158.86
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
Cash Conversion Cycle
-61.46
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
Total Debt/Equity
0.09
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
Interest Cover
21.76
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Alkem Laboratories incorporates wholly owned subsidiary in UAE
    13th Apr 2026, 16:42 PM

    The new entity has been incorporated with a view to export the company’s products to African, South East Asian and non-UAE markets

    Read More
  • Alkem Laboratories launches everyday multivitamin supplement ‘A to Z Daily’
    7th Apr 2026, 16:00 PM

    The product is approved by the Food Safety Standards Authority of India

    Read More
  • Alkem Laboratories incorporates subsidiary in Dubai Healthcare City
    31st Mar 2026, 16:12 PM

    Alkem Pharmaceuticals has been incorporated to undertake the activities of manufacturing products and obtaining product registrations, except trading activities

    Read More
  • Alkem Laboratories launches semaglutide injection in India
    23rd Mar 2026, 10:30 AM

    The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450

    Read More
  • Alkem Laboratories gets certificate of GMP Compliance of Manufacturer for Baddi facility
    16th Mar 2026, 12:00 PM

    The said certificate is valid for a period of three years from the date of inspection

    Read More
  • Alkem Laboratories reports marginal rise in Q3 consolidated net profit
    16th Feb 2026, 09:59 AM

    The consolidated total income of the company increased by 11.90% at Rs 3,879.92 crore for Q3FY26

    Read More
  • USFDA completes pre-approval inspection of manufacturing facility of Alkem Laboratories’ arm
    14th Feb 2026, 13:08 PM

    At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations

    Read More
  • Alkem Laboratories - Quarterly Results
    14th Feb 2026, 00:00 AM

    Read More
  • Alkem Laboratories’ arm to acquire majority stake in Occlutech
    13th Feb 2026, 15:51 PM

    This acquisition represents a significant step in Alkem MedTech’s journey to build a global footprint and enables its entry into advanced cardiovascular devices

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.